MAX

AI Memo

MediaAlpha

As of 2026-09-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q3 P&C execution against company guidance • 2026-09-30

Base target: $11 / p=0% prob

Biggest risk

Q2 gross margin fell to 14.3% from 15.0%, and contribution margin fell to 14.9% from 15.8%. Q3 guidance relies heavily on P&C while Health is expected to be about 1% of revenue. Secondary earnings coverage reported an EPS miss, but no verified post-print analyst estimate or target revisions were supplied [#SEC-8K-2026-07-29] [#PR-EARNINGS-2026-08-31].

Invalidation

Break below $6 or thesis failure.

What would change my mind?

Q2 revenue rose 26% to $316.9 million and adjusted EBITDA rose to $29.3 million; management attributed marketplace strength to broader carrier demand. Q3 guidance and the full-year free-cash-flow outlook provide measurable tests for a recovery from the $9.45 anchor price [#SEC-8K-2026-07-29].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-25

Base target

$11

p=0%

Bull target

$14

p=0%

Bear target

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Free cash flow and repurchase execution
Q2 revenue rose 26% to $316.9 million and adjusted EBITDA rose to $29.3 million; management attributed marketplace strength to broader carrier demand.
Q3 guidance and the full-year free-cash-flow outlook provide measurable tests for a recovery from the $9.45 anchor price [#SEC-8K-2026-07-29].

BearKey bullets

Analyst-target coverage and post-earnings revisions are unverified; the peer set is limited.
P&C carrier advertising demand or share gains may fall short of Q3 guidance [#SEC-8K-2026-07-29].
Q2 gross and contribution margins contracted year over year despite revenue growth [#SEC-8K-2026-07-29].

WatchKey bullets

Q3 P&C execution against company guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $11 (p=0%)

Target spread vs base: +33% / -43%

Scenario probabilities

Bull Target: $14 (p=0%)Base Target: $11 (p=0%)Bear Target: $6 (p=0%)

Commentary

The September 24 anchor of $9.45 is below the prior baseline's $11.04 anchor and the $12.84 level cited by secondary coverage on August 31. This shows continued price weakness, not its cause. Primary Q2 results and guidance are constructive, but margin compression and the decline in shares temper the view. No verified post-print analyst revisions, options, short-interest, employee, or sufficient social-sentiment readings were supplied; sentiment-object zeros mean unavailable, not neutral.

As of 2026-09-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Free cash flow and repurchase execution

Scenarios

Bull Target (Scenario probability)

$14 / p=0% prob

Base Target (Scenario probability)

$11 / p=0% prob

Bear Target (Scenario probability)

$6 / p=0% prob

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
Q3 P&C execution against company guidance
MediaAlpha guided Q3 revenue to $330 million–$355 million and adjusted EBITDA to $32 million–$35 million, citing P&C carrier investment and share gains. Delivery against those ranges is the main operating test; the company expects Health to contribute only about 1% of revenue. September 30 is the quarter-end date, not a confirmed earnings-release date [#SEC-8K-2026-07-29].
Prob 60.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Free cash flow and repurchase execution
2026-12-31
The company maintained a $90 million–$100 million full-year free-cash-flow outlook and expected to complete the vast majority of its remaining buyback authorization during 2026. It also disclosed a September purchase of liabilities for $12.0 million, $10.7 million below their June 30 estimated value. Cash generation and per-share benefits remain to be demonstrated; the liability purchase is already public [#SEC-8K-2026-07-29] [#8-K-2026-09-09].
Prob 60% • Move 9% • Priced-in 50%

Risks

Analyst-target coverage and post-earnings revisions are unverified; the peer set is limited.
P&C carrier advertising demand or share gains may fall short of Q3 guidance [#SEC-8K-2026-07-29].
Q2 gross and contribution margins contracted year over year despite revenue growth [#SEC-8K-2026-07-29].
September Form 4 filings show open-market sales by the chief revenue officer and Steven Yi; these transactions do not establish operating deterioration [#SEC-FORM4-2026-09-16] [#SEC-FORM4-2026-09-02].
The full-year free-cash-flow and repurchase plans may not translate into the expected per-share benefit [#SEC-8K-2026-07-29].

Peers

Symbol	Summary
EVER	EverQuote is the closest identified operating comparison: both depend on insurance-shopping demand and carrier customer-acquisition spending. Business mix and marketplace economics may differ.
QNST	QuinStreet offers a broader performance-marketing comparison with insurance exposure, but its other verticals make it an imperfect valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-25

Loading AI feed…

Symbol

Summary

EVER

EverQuote is the closest identified operating comparison: both depend on insurance-shopping demand and carrier customer-acquisition spending. Business mix and marketplace economics may differ.

QNST

QuinStreet offers a broader performance-marketing comparison with insurance exposure, but its other verticals make it an imperfect valuation peer.